Simon Godwin
Sanofi (United States)(US)Framingham State University(US)
Publications by Year
Research Areas
Virus-based gene therapy research, Viral Infectious Diseases and Gene Expression in Insects, CRISPR and Genetic Engineering, Viral gastroenteritis research and epidemiology, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Distinct Classes of Proteasome-Modulating Agents Cooperatively Augment Recombinant Adeno-Associated Virus Type 2 and Type 5-Mediated Transduction from the Apical Surfaces of Human Airway Epithelia(2004)135 cited
- → AAV2 Vector Harboring a Liver-Restricted Promoter Facilitates Sustained Expression of Therapeutic Levels of α-Galactosidase A and the Induction of Immune Tolerance in Fabry Mice(2003)135 cited
- → Cloning and Sequence Analysis of Human Breast Epithelial Antigen BA46 Reveals an RGD Cell Adhesion Sequence Presented on an Epidermal Growth Factor-Like Domain(1996)72 cited
- → Dual Therapeutic Utility of Proteasome Modulating Agents for Pharmaco-gene Therapy of the Cystic Fibrosis Airway(2004)49 cited
- → Thermal Stability of Adenovirus type 2 as a Function of pH(2006)44 cited
- → An extended model for culture-dependent heterogenous gene expression and proliferation dynamics in mouse embryonic stem cells(2017)26 cited
- → Development of a platform process for adenovirus purification that removes human set and nucleolin and provides high purity vector for gene delivery(2012)11 cited
- → Inverted Fab2s (IFab2s): Engineering and expression of novel, dimeric molecules, with a molecular weight of 100 000(1996)6 cited
- → Environmental Health and Biosafety Risk Assessment Guidance for Commercial-Scale Cell and Gene Therapy Manufacturing(2020)6 cited
- → Environmental Health and Safety Offers a Biosafety Risk Assessment for a Theoretical Model of a Gene Therapy Process Transfer from Research and Development to Large-Scale Manufacturing(2023)2 cited